ASCVD Playbook | Closing the Gaps, One Inning at a Time
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Swing for the Fences – LDL-C as the Power Hitter
Extra Innings – Sustaining Victory Beyond the First Game
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Anjali Owens, MD
Ahmad Masri, MD, MS
Safety in oHCM Therapy: How and When to Transition Treatment?
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Michael Nassif, MD, MSc
Cracking the Code of Obstruction: Unmet Needs in oHCM
Molecular Precision: How Myosin Inhibitors Redefine Control
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Quantifying CKD-aP: Tools for Better Care